Chapter 2

Cash and Capital

Molina's reported operating cash flow was negative $535 million in 2025, its first annual outflow since 2018. Decomposed, the print is mostly government-payment settlement and tax timing, not economic cash burn: cash generation before working capital was roughly positive $754 million. But the reader's test — consistent, non-wavering operating cash — is not what the six-year record shows, and in February 2026 management amended a debt covenant that assumes 2026 earnings stay well below normal. This chapter reconciles the cash, locates it on the balance sheet, and reads the debt.

The negative headline, decomposed

The 2025 outflow is real, but it is not the income statement in disguise. Start from net income of $472 million, add back the non-cash charges every managed-care insurer carries — depreciation and amortization, deferred taxes, share-based compensation — and Molina generated about $754 million of cash before any working-capital movement. The entire swing to a $535 million outflow came from a roughly $1.29 billion working-capital drain, concentrated in two lines: a $591 million reduction in amounts due government agencies (settling prior-period Medicaid risk-corridor and minimum-MLR balances the company had accrued) and a $201 million income-tax payment timing effect [1].

Source: FY2025 Annual Report (Form 10-K), Consolidated Statements of Cash Flows — non-cash add-backs are D&A $195M, deferred taxes $43M, share-based comp $47M, other -$3M [2].

Management's own attribution matches the arithmetic: the year-over-year decline was "driven mainly by Medicaid risk corridor settlement activity, the timing of tax payments, and lower operating performance in the second half of 2025" [3]. Because Molina receives capitation monthly in advance of paying claims, and because state payors can pull premium payments forward or push them back across a period end, the operating cash line is structurally noisier than the earnings it supports [4].

That noise runs both ways, and it is large relative to the business. Over 2020–2025 operating cash flow ranged from a $2.1 billion inflow to the $535 million outflow, while capital expenditure never exceeded $101 million — so free cash flow tracks operating cash almost one-for-one, and the volatility is working capital, not investment.

Source: reported financials, FY2020–FY2025 10-Ks; FY2025 figures per Consolidated Statements of Cash Flows [5].

The honest read cuts both ways. Cumulatively the cash is there: over the six years Molina converted $4.87 billion of net income into $6.56 billion of operating cash — a 1.35× conversion rate that is high, not low, and consistent with a business that collects premium before it pays claims.

Source: derived from reported operating cash flow and net income, FY2020–FY2025 10-Ks [6].

But cumulative conversion is not consistency. For an investor whose framework rewards non-wavering operating cash, the relevant fact is that the annual figure has now printed below net income in three of the last four years — 2022, 2024, and 2025 — as the government-receivable settlement cycle has grown with the premium base. The defensible claim is that Molina's mid-cycle cash generation is real and roughly matches earnings; the claim the record does not support is that it arrives smoothly.

Where the cash actually sits

The balance sheet shows about $8.6 billion of cash and investments against $3.77 billion of long-term debt — a headline that reads like net cash [7]. That net-cash impression does not survive contact with the structure. Most of the cash lives inside regulated health-plan subsidiaries, where roughly $3.1 billion is the statutory minimum capital and surplus those subsidiaries must hold, and where the balance can only move to the parent as a state-approved dividend [8]. The debt sits entirely at the unregulated parent [9].

At the parent itself, cash and investments were $223 million at year-end 2025, down from $445 million a year earlier, and they touched approximately $108 million at the end of the third quarter before recovering [10][11].

Source: FY2025 Annual Report (Form 10-K), MD&A — Financial Condition and Liquidity; statutory minimum is an estimate disclosed by the company [12][13].

The thin parent balance is not the same as a starved parent. The subsidiaries paid $985 million of dividends up to the parent in 2025, after $997 million in 2024 and $705 million in 2023 — a rising, reliable stream of excess statutory capital [14]. The parent's cash cushion thinned not because dividends dried up but because management deployed them: it contributed $439 million back to the subsidiaries for statutory capital, funded the $350 million ConnectiCare acquisition, and repurchased $1.0 billion of stock, part-funded by $838 million of net proceeds from new notes [15][16]. For a reader who treats a net-cash balance sheet as a virtue, the correct adjustment is to ignore the $8.6 billion headline and read the parent on its own: roughly $3.5 billion of net debt at the entity that actually owns the stock, serviced by about $1 billion a year of subsidiary dividends.

Deferred revenue, receivables, and claims payable

Three of the reader's specific balance-sheet tests resolve cleanly, and none flags a warning.

Deferred revenue is negligible and is not debt. Molina carries a deferred revenue line of just $66 million, against $43.1 billion of premium — about half a day of revenue [17]. It is far below the 30-day threshold that would make it a growth signal, and it is immaterial to any net-debt calculation; treating it as debt would move the figure by a rounding error. The company's own economics run the other way — it is paid in advance, so its large current liabilities are claims reserves and government payables, not customer prepayments.

Days in claims payable are stable; the large current liability fell. The medical claims and benefits payable reserve — the insurer's equivalent of inventory — stood at $4,887 million, equal to 47 days in claims payable at year-end, against 48 days a year earlier and 43–46 days through 2025 [18][19]. A stable-to-lower reserve day-count while medical costs were rising is the opposite of the reserve build that would flatter a loss; it argues the 2025 margin break was recognized, not deferred. The other large current liability, amounts due government agencies, actually fell $548 million to $1,326 million as prior-period corridors settled — the balance-sheet mirror of the cash outflow above, and a decline in a payable rather than the suspicious rise the reader watches for [20].

Receivables grew slower than revenue. Receivables rose 7% to $3,533 million while total revenue rose 12%, so days sales outstanding edged down to roughly 30 days of premium — no receivables build masking weak collections [21].

The debt: long-dated and fixed, with one covenant they had to move

The capital structure is conservative and gives the reader little to worry about on refinancing. All $3.8 billion of principal is senior unsecured notes at the parent, fixed-rate, with a weighted-average coupon near 5% and no maturity before 2028. At year-end nothing was drawn on the $1.25 billion revolver or the term loans — in November 2025 the company termed out its floating-rate term-loan borrowings by issuing $850 million of 6.500% notes due 2031, leaving no near-term floating-rate exposure [22].

Source: FY2025 Annual Report (Form 10-K), Note 11 — Debt, contractual maturities table; nothing matures in 2026, 2027, or 2029 [23].

The one place the debt speaks to the through-line is the cost of that reassurance. Interest expense rose to $192 million in 2025 from $118 million, as the company borrowed to fund buybacks and acquisitions and refinanced into higher-coupon notes [24]. Against collapsing operating income, EBIT interest coverage fell from about 14× in 2024 to about 4× in 2025 [25]. Four times still clears the credit agreement's 3.0× minimum on a full-year basis — yet on February 4, 2026 the company amended that agreement to temporarily cut the minimum interest-coverage covenant to 1.75× for all of 2026, stepping back up to 2.00×, 2.50×, and 2.75× through 2027 [26].

That amendment is the sharpest balance-sheet counterweight to the "temporary dislocation" framing carried into this report by Business and Thesis. It does not prove the margin break is permanent — a 2026 trough with rate restoration in 2027 fits both the covenant step-up schedule and management's account. But it is a dated, filed action that presumes the pressure lasts into 2027, not a quarter.

What the cash says, and what would change the read

The cash-generation engine is intact on a multi-year basis and the balance sheet is financed conservatively: mid-cycle operating cash roughly matches earnings, capital intensity is trivial, the debt is long-dated and fixed, and the parent is fed by about $1 billion a year of subsidiary dividends. On the reader's own scorecard, two things fail. First, operating cash is not consistent — it has wavered below net income in three of the last four years and turned negative in 2025 — so the "non-wavering FCF" test is not met on the reported record, however sound the cumulative figure. Second, the net-cash impression from the consolidated balance sheet is an artifact of regulated-subsidiary reserves; the parent that owns the equity carries roughly $3.5 billion of net debt. Two developments would move the read: operating cash returning to positive in 2026 as the government-payable settlements stabilize, and interest coverage climbing back toward the 3.0× the company felt it had to suspend. Both are checkable in the 2026 filings against the exact lines cited here.

Whether that mid-cycle cash is enough — the reader's 8%-plus free-cash-flow-yield bar, and what today's depressed price pays for a normalized figure — is a valuation question this chapter leaves open.